Novartis’ $12B Avidity bet suffers Phase 3 blow
Novartis' Phase 3 trial for del-desiran, a key asset from its $12B Avidity acquisition, showed signs of clinical activity but fell short of primary goals. The company will analyze data and discuss the program's future with regulators. Novartis shares dropped 9% on Sept. 8. Other Avidity programs, del-zota and del-brax, are advancing. Recent setbacks include pelacarsen's failure and cell therapy trial suspensions.
How this was made
The 30-second read
Why it matters
The Phase 3 failure of del‑desiran raises questions about the platform's viability and may trigger further scrutiny of Avidity's pipeline.
Market read
The news caused a sharp 9% drop in NVS stock, highlighting immediate trading relevance.
What to watch
Potential pipeline depth beyond del‑desiran and upcoming data on del‑zota and del‑brax could mitigate the hit.
Background
Novartis announced a $12B acquisition of Avidity in Feb 2026, aiming to leverage its antibody‑oligonucleotide conjugate platform.
Ticker impact
Novartis shares fell ~9% on Sept 8 after Phase 3 failure of del‑desiran, a key asset of its $12B Avidity acquisition.
downward pressure, potential 5‑10% further decline over next few days.
Phase 3 failure of a flagship program undermines the strategic rationale of a multi‑billion acquisition and triggered a sharp intraday sell‑off.
Market effects
Setback may dampen enthusiasm for RNA‑oligonucleotide platforms across biotech sector.
European biotech stocks could see modest pullback as investors reassess RNA delivery risk.
Limited to biotech; broader indices unlikely to be materially affected.
Counterpoint
If the platform can be validated on other targets, the long‑term upside of Avidity may remain intact.
Key entities
- CompanyNovartis
Swiss pharmaceutical giant, ticker NVS.
- CompanyAvidity Biosciences
Acquired biotech focused on RNA delivery platforms.
